Learn Biotech Investing
A structured path through biotech investing — from how the FDA approves drugs to reading clinical readouts, financials, and catalysts. Each topic links the guides, glossary terms, and tools you need.
FDA & Regulatory
How the FDA reviews and approves drugs — PDUFA dates, Advisory Committees, Complete Response Letters, and the expedited pathways (Breakthrough, Fast Track, Accelerated, Priority Review) that shape biotech catalysts.
The Biosimilar Approval Pathway: What Investors Need to Know
How biosimilars are approved via the 351(k) pathway, what interchangeability means, and why biosimilar competition reshapes biotech revenue and patent-cliff dynamics.
FDA Refuse to File (RTF): The Rejection Before the Review
A Refuse to File is the FDA declining to even review an application. Learn what triggers an RTF, how it differs from a Complete Response Letter, and what it signals.
What Is a PDUFA Date Extension? Why the FDA Pushes Back Decisions
PDUFA extensions delay an FDA decision by up to three months. Learn why they happen, whether they're bullish or bearish, and how to interpret them as an investor.
What Is FDA Rolling Review? How It Compresses Drug Timelines
Rolling review lets sponsors submit application sections as they're completed instead of all at once. Here's how it works, who qualifies, and what it means for catalyst timing.
The FDA Accelerated Approval Pathway: A Guide for Investors
How the FDA's Accelerated Approval pathway works, why surrogate endpoints matter, the confirmatory-trial obligation, and the withdrawal risk investors must price in.
FDA Fast Track Designation Explained for Biotech Investors
What FDA Fast Track designation means, how a drug qualifies, the benefits it confers, and how investors should interpret it relative to Breakthrough Therapy and Priority Review.
Orphan Drug Designation: Why Rare Disease Drugs Are a Strategic Goldmine
Understand FDA Orphan Drug Designation, its financial incentives, market exclusivity benefits, and why rare disease biotech companies attract premium valuations.
FDA Priority Review vs. Standard Review: What the Difference Means for Biotech Investors
Compare FDA Priority Review and Standard Review timelines, learn what triggers each designation, and understand how review type affects drug approval probability and stock prices.
FDA Breakthrough Therapy Designation: What It Means for Drug Development and Investors
Understand what FDA Breakthrough Therapy Designation is, how it accelerates drug development, approval success rates, and investment implications for biotech stocks.
FDA Complete Response Letters (CRLs): What They Mean for Biotech Investors
Learn what a Complete Response Letter is, why the FDA issues CRLs, how companies respond, and what CRL outcomes mean for biotech stock prices and timelines.
What Is PDUFA? A Complete Guide for Biotech Investors
Understand PDUFA dates, how the FDA review process works, and why PDUFA action dates are the most important catalysts in biotech investing.
How to Read FDA Advisory Committee (AdCom) Meeting Results
Learn how FDA Advisory Committee meetings work, how to interpret voting results, and what AdCom outcomes mean for biotech stock prices.
Clinical Trials & Data Readouts
How drugs move through Phase 1–3 testing, what endpoints and topline data mean, and how to read a clinical trial like an analyst.
The Biosimilar Approval Pathway: What Investors Need to Know
How biosimilars are approved via the 351(k) pathway, what interchangeability means, and why biosimilar competition reshapes biotech revenue and patent-cliff dynamics.
Surrogate Endpoints in Oncology: ORR, PFS, and Overall Survival
How oncology surrogate endpoints like ORR and PFS relate to overall survival, why they enable faster approvals, and the risks investors must weigh when survival data lag.
Understanding Mechanism of Action (MoA) in Biotech Investing
Why a drug's mechanism of action drives differentiation, competitive risk, and side effects, and how investors can use MoA to evaluate a pipeline without a science degree.
Bispecific Antibodies Explained: Two Targets, One Molecule
How bispecific antibodies engage two targets at once, why T-cell engagers are reshaping oncology, and what investors should weigh versus ADCs and CAR-T.
FDA Refuse to File (RTF): The Rejection Before the Review
A Refuse to File is the FDA declining to even review an application. Learn what triggers an RTF, how it differs from a Complete Response Letter, and what it signals.
How to Read ClinicalTrials.gov Like an Analyst
A practical guide to mining ClinicalTrials.gov for investment signals — status changes, enrollment, endpoints, completion dates, and the red flags hidden in trial records.
Clinical Trial Enrollment and Timelines: Reading the Real Schedule
Why enrollment pace, not the protocol, usually drives a trial's timeline, how to spot delays early, and what slow enrollment signals about a biotech's catalysts and cash.
mRNA Platforms Beyond Vaccines: The Investment Thesis
How mRNA technology works, why it's a platform rather than a single product, and the opportunities and challenges as developers push beyond vaccines into therapeutics.
What Is FDA Rolling Review? How It Compresses Drug Timelines
Rolling review lets sponsors submit application sections as they're completed instead of all at once. Here's how it works, who qualifies, and what it means for catalyst timing.
Gene Therapy and AAV Vectors Explained for Investors
How AAV-based gene therapies deliver a working gene, the durability and manufacturing questions that define them, and the unique commercial model of one-time cures.
Open-Label vs. Double-Blind Trials: Why Trial Design Matters
How blinding and randomization affect the reliability of clinical data, why open-label results carry more bias risk, and what investors should weigh when a trial reads out.
The FDA Accelerated Approval Pathway: A Guide for Investors
How the FDA's Accelerated Approval pathway works, why surrogate endpoints matter, the confirmatory-trial obligation, and the withdrawal risk investors must price in.
CAR-T Cell Therapy Explained for Investors
How CAR-T re-engineers a patient's immune cells to fight cancer, the manufacturing and safety challenges that shape its economics, and what investors should watch.
Statistical Significance and P-Values in Clinical Trials
What a p-value actually means, why p<0.05 is the bar, the difference between statistical and clinical significance, and how to avoid being fooled by a 'trend.'
Primary vs. Secondary Endpoints: Reading a Trial the Right Way
Why the primary endpoint determines a trial's success or failure, how secondary and exploratory endpoints fit in, and the traps investors fall into when a study 'misses.'
FDA Fast Track Designation Explained for Biotech Investors
What FDA Fast Track designation means, how a drug qualifies, the benefits it confers, and how investors should interpret it relative to Breakthrough Therapy and Priority Review.
What Is an Antibody-Drug Conjugate (ADC)? An Investor's Primer
How antibody-drug conjugates deliver potent payloads to cancer cells, the three components that define them, and why ADCs have become one of oncology's hottest modalities.
Biotech Competitive Landscape Analysis: How to Map Drug Pipelines and Identify Winners
Learn how to analyze the competitive landscape in biotech, compare drug pipelines across companies, evaluate first-mover advantage, and identify best-in-class opportunities.
Orphan Drug Designation: Why Rare Disease Drugs Are a Strategic Goldmine
Understand FDA Orphan Drug Designation, its financial incentives, market exclusivity benefits, and why rare disease biotech companies attract premium valuations.
Phase 3 Trial Endpoints Explained: P-Values, Hazard Ratios, and What Investors Need to Know
Demystify clinical trial statistics for biotech investing. Learn how to interpret p-values, hazard ratios, confidence intervals, and primary endpoints in Phase 3 trials.
Patent Expiry in Biotech: How Loss of Exclusivity Impacts Stock Valuations
Understand patent cliffs in biotech and pharma, how loss of exclusivity affects revenue and stock prices, and strategies for investing around patent expiration events.
FDA Breakthrough Therapy Designation: What It Means for Drug Development and Investors
Understand what FDA Breakthrough Therapy Designation is, how it accelerates drug development, approval success rates, and investment implications for biotech stocks.
Biotech Clinical Trial Phases Explained: What Investors Need to Know
A comprehensive guide to Phase 1, Phase 2, and Phase 3 clinical trials — what happens at each stage, success rates, and what results mean for biotech stocks.
Biotech Finance & SEC Filings
Reading the numbers behind a biotech — cash runway, burn rate, dilution, valuation, and the SEC filings (10-K, 10-Q, 8-K, S-1, Form 4, 13F) where the evidence lives.
The Biosimilar Approval Pathway: What Investors Need to Know
How biosimilars are approved via the 351(k) pathway, what interchangeability means, and why biosimilar competition reshapes biotech revenue and patent-cliff dynamics.
Biotech Valuation with rNPV: Pricing Pipelines Under Risk
How risk-adjusted net present value (rNPV) values a clinical-stage pipeline, why probability of success drives everything, and how to use it without fooling yourself.
Surrogate Endpoints in Oncology: ORR, PFS, and Overall Survival
How oncology surrogate endpoints like ORR and PFS relate to overall survival, why they enable faster approvals, and the risks investors must weigh when survival data lag.
Understanding Mechanism of Action (MoA) in Biotech Investing
Why a drug's mechanism of action drives differentiation, competitive risk, and side effects, and how investors can use MoA to evaluate a pipeline without a science degree.
13F Filings: Tracking Institutional Money in Biotech
How to use quarterly 13F filings to see which funds are building or exiting biotech positions, what the data can and can't tell you, and the timing pitfalls to avoid.
Bispecific Antibodies Explained: Two Targets, One Molecule
How bispecific antibodies engage two targets at once, why T-cell engagers are reshaping oncology, and what investors should weigh versus ADCs and CAR-T.
How to Read ClinicalTrials.gov Like an Analyst
A practical guide to mining ClinicalTrials.gov for investment signals — status changes, enrollment, endpoints, completion dates, and the red flags hidden in trial records.
Clinical Trial Enrollment and Timelines: Reading the Real Schedule
Why enrollment pace, not the protocol, usually drives a trial's timeline, how to spot delays early, and what slow enrollment signals about a biotech's catalysts and cash.
How to Screen for Undervalued Biotech Stocks
A practical framework for screening biotech — combining cash, catalysts, pipeline quality, and valuation — and how natural-language screening speeds the hunt.
mRNA Platforms Beyond Vaccines: The Investment Thesis
How mRNA technology works, why it's a platform rather than a single product, and the opportunities and challenges as developers push beyond vaccines into therapeutics.
Royalty and Milestone Deals: How Biotech Partnerships Create Value
How upfront payments, milestones, and royalties work in biotech licensing and partnership deals, and why they're a key non-dilutive financing and validation signal.
Gene Therapy and AAV Vectors Explained for Investors
How AAV-based gene therapies deliver a working gene, the durability and manufacturing questions that define them, and the unique commercial model of one-time cures.
Patent Cliffs and Loss of Exclusivity in Biotech
How patent expiry and loss of exclusivity reshape pharma revenue, the difference between small-molecule generics and biosimilars, and how investors model the cliff.
Going Concern Warnings: The Biotech Red Flag in the Footnotes
What a going concern qualification means, why it's common in clinical-stage biotech, and how investors should weigh it against the pipeline and catalyst timeline.
The FDA Accelerated Approval Pathway: A Guide for Investors
How the FDA's Accelerated Approval pathway works, why surrogate endpoints matter, the confirmatory-trial obligation, and the withdrawal risk investors must price in.
Building a Biotech Catalyst Calendar That Actually Works
How to build and maintain a catalyst calendar for biotech investing — which events to track, where the dates come from, and why a stale calendar is worse than none.
CAR-T Cell Therapy Explained for Investors
How CAR-T re-engineers a patient's immune cells to fight cancer, the manufacturing and safety challenges that shape its economics, and what investors should watch.
How to Read a Biotech 10-K: The Sections That Actually Matter
A focused guide to the annual 10-K for biotech investors — risk factors, liquidity, pipeline disclosures, and the footnotes where the real story often hides.
Statistical Significance and P-Values in Clinical Trials
What a p-value actually means, why p<0.05 is the bar, the difference between statistical and clinical significance, and how to avoid being fooled by a 'trend.'
Binary Events and Biotech Volatility: Managing the Big Swings
Why biotech stocks move violently on single catalysts, how to think about binary risk and position sizing, and the behavioral traps around make-or-break events.
Biotech Dilution and ATM Offerings: The Financing Treadmill
Why clinical-stage biotechs dilute constantly, how at-the-market (ATM) offerings work, and how to assess financing risk before it hits the share count.
Primary vs. Secondary Endpoints: Reading a Trial the Right Way
Why the primary endpoint determines a trial's success or failure, how secondary and exploratory endpoints fit in, and the traps investors fall into when a study 'misses.'
FDA Fast Track Designation Explained for Biotech Investors
What FDA Fast Track designation means, how a drug qualifies, the benefits it confers, and how investors should interpret it relative to Breakthrough Therapy and Priority Review.
What Is an Antibody-Drug Conjugate (ADC)? An Investor's Primer
How antibody-drug conjugates deliver potent payloads to cancer cells, the three components that define them, and why ADCs have become one of oncology's hottest modalities.
Biotech Competitive Landscape Analysis: How to Map Drug Pipelines and Identify Winners
Learn how to analyze the competitive landscape in biotech, compare drug pipelines across companies, evaluate first-mover advantage, and identify best-in-class opportunities.
How to Screen Biotech Stocks with Natural Language: Beyond Traditional Stock Screeners
Discover how natural language screening lets biotech investors filter companies using plain English queries, replacing complex spreadsheet-based screening with intuitive AI-powered search.
Orphan Drug Designation: Why Rare Disease Drugs Are a Strategic Goldmine
Understand FDA Orphan Drug Designation, its financial incentives, market exclusivity benefits, and why rare disease biotech companies attract premium valuations.
Biotech Earnings Reports: Key Metrics Beyond Revenue That Drive Stock Prices
Learn what to look for in biotech quarterly earnings reports, from cash burn and pipeline updates to guidance changes and hidden signals that move stock prices.
FDA Priority Review vs. Standard Review: What the Difference Means for Biotech Investors
Compare FDA Priority Review and Standard Review timelines, learn what triggers each designation, and understand how review type affects drug approval probability and stock prices.
Phase 3 Trial Endpoints Explained: P-Values, Hazard Ratios, and What Investors Need to Know
Demystify clinical trial statistics for biotech investing. Learn how to interpret p-values, hazard ratios, confidence intervals, and primary endpoints in Phase 3 trials.
Biotech Insider Trading Signals: What Form 4 Filings Reveal About Stock Direction
Learn how to interpret SEC Form 4 insider trading filings for biotech companies, identify meaningful insider buying patterns, and avoid common misinterpretations.
Patent Expiry in Biotech: How Loss of Exclusivity Impacts Stock Valuations
Understand patent cliffs in biotech and pharma, how loss of exclusivity affects revenue and stock prices, and strategies for investing around patent expiration events.
Biotech Cash Runway Analysis: How to Evaluate Financial Health Before It's Too Late
Learn how to calculate biotech cash runway, identify dilution risk, interpret burn rate trends, and use financial data to time your biotech investments.
FDA Breakthrough Therapy Designation: What It Means for Drug Development and Investors
Understand what FDA Breakthrough Therapy Designation is, how it accelerates drug development, approval success rates, and investment implications for biotech stocks.
FDA Complete Response Letters (CRLs): What They Mean for Biotech Investors
Learn what a Complete Response Letter is, why the FDA issues CRLs, how companies respond, and what CRL outcomes mean for biotech stock prices and timelines.
What Is PDUFA? A Complete Guide for Biotech Investors
Understand PDUFA dates, how the FDA review process works, and why PDUFA action dates are the most important catalysts in biotech investing.
How to Read FDA Advisory Committee (AdCom) Meeting Results
Learn how FDA Advisory Committee meetings work, how to interpret voting results, and what AdCom outcomes mean for biotech stock prices.
Biotech Clinical Trial Phases Explained: What Investors Need to Know
A comprehensive guide to Phase 1, Phase 2, and Phase 3 clinical trials — what happens at each stage, success rates, and what results mean for biotech stocks.
SEC Filing Analysis for Biotech Companies: Key Filings Every Investor Should Read
Learn which SEC filings matter most for biotech companies, what to look for in 10-K, 10-Q, 8-K, and S-1 filings, and how to extract actionable insights.
How AI Is Transforming Biotech Investment Research
Explore how artificial intelligence is changing biotech due diligence — from automated data extraction to multi-agent analysis and natural language screening.
Drug Modalities & Science
The science behind modern therapeutics — antibody-drug conjugates, CAR-T cell therapy, and how a drug’s mechanism of action drives differentiation and risk.
The Biosimilar Approval Pathway: What Investors Need to Know
How biosimilars are approved via the 351(k) pathway, what interchangeability means, and why biosimilar competition reshapes biotech revenue and patent-cliff dynamics.
Surrogate Endpoints in Oncology: ORR, PFS, and Overall Survival
How oncology surrogate endpoints like ORR and PFS relate to overall survival, why they enable faster approvals, and the risks investors must weigh when survival data lag.
Understanding Mechanism of Action (MoA) in Biotech Investing
Why a drug's mechanism of action drives differentiation, competitive risk, and side effects, and how investors can use MoA to evaluate a pipeline without a science degree.
Bispecific Antibodies Explained: Two Targets, One Molecule
How bispecific antibodies engage two targets at once, why T-cell engagers are reshaping oncology, and what investors should weigh versus ADCs and CAR-T.
FDA Refuse to File (RTF): The Rejection Before the Review
A Refuse to File is the FDA declining to even review an application. Learn what triggers an RTF, how it differs from a Complete Response Letter, and what it signals.
Clinical Trial Enrollment and Timelines: Reading the Real Schedule
Why enrollment pace, not the protocol, usually drives a trial's timeline, how to spot delays early, and what slow enrollment signals about a biotech's catalysts and cash.
mRNA Platforms Beyond Vaccines: The Investment Thesis
How mRNA technology works, why it's a platform rather than a single product, and the opportunities and challenges as developers push beyond vaccines into therapeutics.
What Is FDA Rolling Review? How It Compresses Drug Timelines
Rolling review lets sponsors submit application sections as they're completed instead of all at once. Here's how it works, who qualifies, and what it means for catalyst timing.
Gene Therapy and AAV Vectors Explained for Investors
How AAV-based gene therapies deliver a working gene, the durability and manufacturing questions that define them, and the unique commercial model of one-time cures.
Open-Label vs. Double-Blind Trials: Why Trial Design Matters
How blinding and randomization affect the reliability of clinical data, why open-label results carry more bias risk, and what investors should weigh when a trial reads out.
The FDA Accelerated Approval Pathway: A Guide for Investors
How the FDA's Accelerated Approval pathway works, why surrogate endpoints matter, the confirmatory-trial obligation, and the withdrawal risk investors must price in.
CAR-T Cell Therapy Explained for Investors
How CAR-T re-engineers a patient's immune cells to fight cancer, the manufacturing and safety challenges that shape its economics, and what investors should watch.
Statistical Significance and P-Values in Clinical Trials
What a p-value actually means, why p<0.05 is the bar, the difference between statistical and clinical significance, and how to avoid being fooled by a 'trend.'
Primary vs. Secondary Endpoints: Reading a Trial the Right Way
Why the primary endpoint determines a trial's success or failure, how secondary and exploratory endpoints fit in, and the traps investors fall into when a study 'misses.'
FDA Fast Track Designation Explained for Biotech Investors
What FDA Fast Track designation means, how a drug qualifies, the benefits it confers, and how investors should interpret it relative to Breakthrough Therapy and Priority Review.
What Is an Antibody-Drug Conjugate (ADC)? An Investor's Primer
How antibody-drug conjugates deliver potent payloads to cancer cells, the three components that define them, and why ADCs have become one of oncology's hottest modalities.
Biotech Competitive Landscape Analysis: How to Map Drug Pipelines and Identify Winners
Learn how to analyze the competitive landscape in biotech, compare drug pipelines across companies, evaluate first-mover advantage, and identify best-in-class opportunities.
Orphan Drug Designation: Why Rare Disease Drugs Are a Strategic Goldmine
Understand FDA Orphan Drug Designation, its financial incentives, market exclusivity benefits, and why rare disease biotech companies attract premium valuations.
Phase 3 Trial Endpoints Explained: P-Values, Hazard Ratios, and What Investors Need to Know
Demystify clinical trial statistics for biotech investing. Learn how to interpret p-values, hazard ratios, confidence intervals, and primary endpoints in Phase 3 trials.
Patent Expiry in Biotech: How Loss of Exclusivity Impacts Stock Valuations
Understand patent cliffs in biotech and pharma, how loss of exclusivity affects revenue and stock prices, and strategies for investing around patent expiration events.
FDA Breakthrough Therapy Designation: What It Means for Drug Development and Investors
Understand what FDA Breakthrough Therapy Designation is, how it accelerates drug development, approval success rates, and investment implications for biotech stocks.
Biotech Clinical Trial Phases Explained: What Investors Need to Know
A comprehensive guide to Phase 1, Phase 2, and Phase 3 clinical trials — what happens at each stage, success rates, and what results mean for biotech stocks.
Investing Strategy & Catalysts
Putting it together — building a catalyst calendar, navigating binary events, screening for value, and using AI-powered research for biotech due diligence.
The Biosimilar Approval Pathway: What Investors Need to Know
How biosimilars are approved via the 351(k) pathway, what interchangeability means, and why biosimilar competition reshapes biotech revenue and patent-cliff dynamics.
Biotech Valuation with rNPV: Pricing Pipelines Under Risk
How risk-adjusted net present value (rNPV) values a clinical-stage pipeline, why probability of success drives everything, and how to use it without fooling yourself.
Surrogate Endpoints in Oncology: ORR, PFS, and Overall Survival
How oncology surrogate endpoints like ORR and PFS relate to overall survival, why they enable faster approvals, and the risks investors must weigh when survival data lag.
Understanding Mechanism of Action (MoA) in Biotech Investing
Why a drug's mechanism of action drives differentiation, competitive risk, and side effects, and how investors can use MoA to evaluate a pipeline without a science degree.
13F Filings: Tracking Institutional Money in Biotech
How to use quarterly 13F filings to see which funds are building or exiting biotech positions, what the data can and can't tell you, and the timing pitfalls to avoid.
Bispecific Antibodies Explained: Two Targets, One Molecule
How bispecific antibodies engage two targets at once, why T-cell engagers are reshaping oncology, and what investors should weigh versus ADCs and CAR-T.
How to Read ClinicalTrials.gov Like an Analyst
A practical guide to mining ClinicalTrials.gov for investment signals — status changes, enrollment, endpoints, completion dates, and the red flags hidden in trial records.
Clinical Trial Enrollment and Timelines: Reading the Real Schedule
Why enrollment pace, not the protocol, usually drives a trial's timeline, how to spot delays early, and what slow enrollment signals about a biotech's catalysts and cash.
How to Screen for Undervalued Biotech Stocks
A practical framework for screening biotech — combining cash, catalysts, pipeline quality, and valuation — and how natural-language screening speeds the hunt.
mRNA Platforms Beyond Vaccines: The Investment Thesis
How mRNA technology works, why it's a platform rather than a single product, and the opportunities and challenges as developers push beyond vaccines into therapeutics.
Royalty and Milestone Deals: How Biotech Partnerships Create Value
How upfront payments, milestones, and royalties work in biotech licensing and partnership deals, and why they're a key non-dilutive financing and validation signal.
What Is a PDUFA Date Extension? Why the FDA Pushes Back Decisions
PDUFA extensions delay an FDA decision by up to three months. Learn why they happen, whether they're bullish or bearish, and how to interpret them as an investor.
Gene Therapy and AAV Vectors Explained for Investors
How AAV-based gene therapies deliver a working gene, the durability and manufacturing questions that define them, and the unique commercial model of one-time cures.
Patent Cliffs and Loss of Exclusivity in Biotech
How patent expiry and loss of exclusivity reshape pharma revenue, the difference between small-molecule generics and biosimilars, and how investors model the cliff.
Going Concern Warnings: The Biotech Red Flag in the Footnotes
What a going concern qualification means, why it's common in clinical-stage biotech, and how investors should weigh it against the pipeline and catalyst timeline.
The FDA Accelerated Approval Pathway: A Guide for Investors
How the FDA's Accelerated Approval pathway works, why surrogate endpoints matter, the confirmatory-trial obligation, and the withdrawal risk investors must price in.
Building a Biotech Catalyst Calendar That Actually Works
How to build and maintain a catalyst calendar for biotech investing — which events to track, where the dates come from, and why a stale calendar is worse than none.
CAR-T Cell Therapy Explained for Investors
How CAR-T re-engineers a patient's immune cells to fight cancer, the manufacturing and safety challenges that shape its economics, and what investors should watch.
How to Read a Biotech 10-K: The Sections That Actually Matter
A focused guide to the annual 10-K for biotech investors — risk factors, liquidity, pipeline disclosures, and the footnotes where the real story often hides.
Statistical Significance and P-Values in Clinical Trials
What a p-value actually means, why p<0.05 is the bar, the difference between statistical and clinical significance, and how to avoid being fooled by a 'trend.'
Binary Events and Biotech Volatility: Managing the Big Swings
Why biotech stocks move violently on single catalysts, how to think about binary risk and position sizing, and the behavioral traps around make-or-break events.
Biotech Dilution and ATM Offerings: The Financing Treadmill
Why clinical-stage biotechs dilute constantly, how at-the-market (ATM) offerings work, and how to assess financing risk before it hits the share count.
Primary vs. Secondary Endpoints: Reading a Trial the Right Way
Why the primary endpoint determines a trial's success or failure, how secondary and exploratory endpoints fit in, and the traps investors fall into when a study 'misses.'
FDA Fast Track Designation Explained for Biotech Investors
What FDA Fast Track designation means, how a drug qualifies, the benefits it confers, and how investors should interpret it relative to Breakthrough Therapy and Priority Review.
What Is an Antibody-Drug Conjugate (ADC)? An Investor's Primer
How antibody-drug conjugates deliver potent payloads to cancer cells, the three components that define them, and why ADCs have become one of oncology's hottest modalities.
Biotech Competitive Landscape Analysis: How to Map Drug Pipelines and Identify Winners
Learn how to analyze the competitive landscape in biotech, compare drug pipelines across companies, evaluate first-mover advantage, and identify best-in-class opportunities.
How to Screen Biotech Stocks with Natural Language: Beyond Traditional Stock Screeners
Discover how natural language screening lets biotech investors filter companies using plain English queries, replacing complex spreadsheet-based screening with intuitive AI-powered search.
Orphan Drug Designation: Why Rare Disease Drugs Are a Strategic Goldmine
Understand FDA Orphan Drug Designation, its financial incentives, market exclusivity benefits, and why rare disease biotech companies attract premium valuations.
Biotech Earnings Reports: Key Metrics Beyond Revenue That Drive Stock Prices
Learn what to look for in biotech quarterly earnings reports, from cash burn and pipeline updates to guidance changes and hidden signals that move stock prices.
FDA Priority Review vs. Standard Review: What the Difference Means for Biotech Investors
Compare FDA Priority Review and Standard Review timelines, learn what triggers each designation, and understand how review type affects drug approval probability and stock prices.
Phase 3 Trial Endpoints Explained: P-Values, Hazard Ratios, and What Investors Need to Know
Demystify clinical trial statistics for biotech investing. Learn how to interpret p-values, hazard ratios, confidence intervals, and primary endpoints in Phase 3 trials.
Biotech Insider Trading Signals: What Form 4 Filings Reveal About Stock Direction
Learn how to interpret SEC Form 4 insider trading filings for biotech companies, identify meaningful insider buying patterns, and avoid common misinterpretations.
Patent Expiry in Biotech: How Loss of Exclusivity Impacts Stock Valuations
Understand patent cliffs in biotech and pharma, how loss of exclusivity affects revenue and stock prices, and strategies for investing around patent expiration events.
Biotech Cash Runway Analysis: How to Evaluate Financial Health Before It's Too Late
Learn how to calculate biotech cash runway, identify dilution risk, interpret burn rate trends, and use financial data to time your biotech investments.
FDA Breakthrough Therapy Designation: What It Means for Drug Development and Investors
Understand what FDA Breakthrough Therapy Designation is, how it accelerates drug development, approval success rates, and investment implications for biotech stocks.
FDA Complete Response Letters (CRLs): What They Mean for Biotech Investors
Learn what a Complete Response Letter is, why the FDA issues CRLs, how companies respond, and what CRL outcomes mean for biotech stock prices and timelines.
What Is PDUFA? A Complete Guide for Biotech Investors
Understand PDUFA dates, how the FDA review process works, and why PDUFA action dates are the most important catalysts in biotech investing.
How to Read FDA Advisory Committee (AdCom) Meeting Results
Learn how FDA Advisory Committee meetings work, how to interpret voting results, and what AdCom outcomes mean for biotech stock prices.
Biotech Clinical Trial Phases Explained: What Investors Need to Know
A comprehensive guide to Phase 1, Phase 2, and Phase 3 clinical trials — what happens at each stage, success rates, and what results mean for biotech stocks.
SEC Filing Analysis for Biotech Companies: Key Filings Every Investor Should Read
Learn which SEC filings matter most for biotech companies, what to look for in 10-K, 10-Q, 8-K, and S-1 filings, and how to extract actionable insights.
How AI Is Transforming Biotech Investment Research
Explore how artificial intelligence is changing biotech due diligence — from automated data extraction to multi-agent analysis and natural language screening.